Malastad (Proguanil Hydrochloride, Atovaquone)

Atovaquone inhibits the mitochondrial electron transport chain of Plasmodium parasites, disrupting energy production. Proguanil hydrochloride acts as a dihydrofolate reductase inhibitor, interfering with folate metabolism. Together they create a synergistic effect that kills the parasite more efficiently than either agent alone.

The dosage of Malastad is determined by a qualified prescriber based on the indication, patient weight, age, renal and hepatic function, and local treatment guidelines. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for Malastad in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the prescribing clinician in consultation with the patient.

To order Malastad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Malastad combines two agents with complementary mechanisms, offering higher efficacy and reduced resistance risk compared with single‑component drugs such as chloroquine or mefloquine. It is generally preferred for areas with known resistance to older agents, though choice depends on local resistance patterns and patient factors.

Malastad tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Malastad is taken orally with a full glass of water, preferably with food or a milky drink to enhance absorption of atovaquone. The tablets should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include severe allergic reactions such as anaphylaxis, hepatic dysfunction, Stevens‑Johnson syndrome, severe neutropenia, and hemolytic anemia. Patients should seek immediate medical attention if they develop rash, fever, jaundice, unexplained bruising, or breathing difficulties.

Malastad should be avoided in individuals with known hypersensitivity to proguanil, atovaquone, or any tablet excipients. Caution is advised for patients with severe renal or hepatic impairment, and it is contraindicated when monotherapy is required for resistant malaria strains.